Study identifier:D1520C05285
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An Open, Randomised, 2-way Crossover Study to Establish the Absolute Bioavailability of AZD9056 in Tablet Formulation (200 mg) Compared With and Intravenous Formulation (25 mg), in Healthy Volunteers
Rheumatoid Arthritis
Phase 1
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|